1. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study
- Author
-
Xiaosheng Fang, Yasuharu Sato, Paolo Strati, Wenbin Qian, Fredrick B. Hagemeister, Zhaoming Wang, Ling Li, Jian Li, Noriko Iwaki, Li Yu, Ruifang Sun, Ken H. Young, Hanjin Yang, Menghan Shi, Zijun Y. Xu-Monette, Qingqing Cai, Eric Oksenhendler, Shanxiang Zhang, Lu Zhang, Jianyong Li, and Qiongli Zhai
- Subjects
Adult ,Oncology ,China ,Cancer Research ,medicine.medical_specialty ,Constitutional symptoms ,Hematologic Malignancies ,medicine.medical_treatment ,Disease ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Disease severity ,Internal medicine ,medicine ,Humans ,Chemotherapy ,urogenital system ,business.industry ,Castleman Disease ,Castleman disease ,medicine.disease ,Treatment Outcome ,030220 oncology & carcinogenesis ,Herpesvirus 8, Human ,Multicentric Castleman Disease ,business ,Watchful waiting ,030215 immunology - Abstract
Background Patients with multicentric Castleman disease (MCD) who are negative for human immunodeficiency virus and human herpesvirus 8 are considered to have idiopathic MCD (iMCD). The clinical presentation of iMCD varies from mild constitutional symptoms to life-threatening symptoms or death. The treatment strategy varies from “watchful waiting” to high-dose chemotherapy. This diverse clinical presentation calls for a classification stratification system that takes into account the severity of the disease. Subjects, Materials, and Methods We analyzed the clinical, laboratory, and pathologic abnormalities and treatment outcomes of 176 patients with iMCD (median follow-up duration 12 years) from the U.S. and China to better understand the characteristics and prognostic factors of this disease. This discovery set of iMCD results was confirmed from the validation set composed of additional 197 patients with iMCD organized from The International Castleman Disease Consortium. Results Using these data, we proposed and validated the iMCD international prognostic index (iMCD-IPI), which includes parameters related to patient characteristics (age > 40 years), histopathologic features (plasma cell variant), and inflammatory consequences of iMCD (hepatomegaly and/or splenomegaly, hemoglobin Conclusion This study represents the largest series of studies on patients with iMCD in the field and proposed a novel risk-stratification model for iMCD-IPI that could be used to guide risk-stratified treatment strategies in patients with iMCD. Implications for Practice Patients with idiopathic multicentric Castleman disease (iMCD) can benefit from care based on clinical symptoms and disease severity. This study in 176 patients with iMCD constructed an iMCD-IPI score based on five clinical factors, including age >40 years, plasmacytic variant subtype, hepatomegaly and/or splenomegaly, hemoglobin
- Published
- 2020